209 related articles for article (PubMed ID: 11569989)
21. Nukes linked to fat wasting.
TreatmentUpdate; 2001; 12(10):4-5. PubMed ID: 11570064
[No Abstract] [Full Text] [Related]
22. Editorial comment: tenofovir-related nephrotoxicity--who's at risk?
Gupta Samir K
AIDS Read; 2007 Feb; 17(2):102-3. PubMed ID: 17323509
[No Abstract] [Full Text] [Related]
23. Lipodrama.
Horn T
Res Initiat Treat Action; 1999 Dec; 5(5):13-5. PubMed ID: 11366885
[TBL] [Abstract][Full Text] [Related]
24. [Lipodystrophy and 'buffalo hump' during treatment with HIV protease inhibitors].
Dieleman JP; Hillebrand-Haverkort ME; van der Ende ME; Sturkenboom MC; Lange JM; Stricker BH
Ned Tijdschr Geneeskd; 1998 Dec; 142(52):2856-60. PubMed ID: 10065260
[TBL] [Abstract][Full Text] [Related]
25. Are changes in body shape linked to viral load.
TreatmentUpdate; 1999 Jun; 11(4):4-5. PubMed ID: 11366791
[TBL] [Abstract][Full Text] [Related]
26. Patient adherence, not viral load now most important in HIV therapy.
Rep Med Guidel Outcomes Res; 2000 Feb; 11(3):6-7. PubMed ID: 11768406
[No Abstract] [Full Text] [Related]
27. PI/NRTI "sparing" regimens for HIV infection. IAPAC sessions 2001, July 18-19, 2001 - Chicago.
Cohen C
IAPAC Mon; 2001 Aug; 7(8):254-60. PubMed ID: 11708281
[No Abstract] [Full Text] [Related]
28. Are changes in body shape due to drug side effects?
TreatmentUpdate; 1999 Jun; 11(4):3-4. PubMed ID: 11366790
[TBL] [Abstract][Full Text] [Related]
29. Double jeopardy: the hazards of drug-drug interactions.
Flexner C
Res Initiat Treat Action; 1998 Dec; 4(7):3-8. PubMed ID: 11366084
[TBL] [Abstract][Full Text] [Related]
30. Lipodystrophy--introduction.
TreatmentUpdate; 2001; 13(7):2-3. PubMed ID: 11794857
[No Abstract] [Full Text] [Related]
31. Anti-HIV agents. A second study confirms fat loss issues with efavirenz.
TreatmentUpdate; 2007 Feb; 19(2):6-7. PubMed ID: 17447314
[No Abstract] [Full Text] [Related]
32. [Increased girth, thin arms. Unusual changes in HIV therapy].
MMW Fortschr Med; 1999 Sep; 141(36):62-3. PubMed ID: 10904607
[No Abstract] [Full Text] [Related]
33. Cushing's syndrome mimicking lipodystrophy syndrome in a patient with AIDS.
Bates SM; Page KB; Nakielny RA; Talbot MD
Int J STD AIDS; 2002 Sep; 13(9):648-9. PubMed ID: 12243135
[No Abstract] [Full Text] [Related]
34. Toxicity of antiretroviral therapy and implications for drug development.
Carr A
Nat Rev Drug Discov; 2003 Aug; 2(8):624-34. PubMed ID: 12904812
[No Abstract] [Full Text] [Related]
35. A randomized controlled trial investigating the efficacy and safety of switching from a protease inhibitor to nevirapine in patients with undetectable viral load.
Arranz Caso JA; López JC; Santos I; Estrada V; Castilla V; Sanz J; Sanz J; Molina JP; Fernández Guerrero M; Górgolas M
HIV Med; 2005 Sep; 6(5):353-9. PubMed ID: 16156884
[TBL] [Abstract][Full Text] [Related]
36. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
37. Anti-HIV drug update.
Proj Inf Perspect; 2000 Aug; (30):5-6. PubMed ID: 12171015
[TBL] [Abstract][Full Text] [Related]
38. Buffalo hump: what the experts suggest.
Piliero PJ; McComsey GA
AIDS Clin Care; 2004 Mar; 16(3):22-3. PubMed ID: 15119294
[No Abstract] [Full Text] [Related]
39. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
[No Abstract] [Full Text] [Related]
40. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
Lagathu C; Bastard JP; Auclair M; Maachi M; Kornprobst M; Capeau J; Caron M
Antivir Ther; 2004 Dec; 9(6):911-20. PubMed ID: 15651750
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
